Crizanlizumab to help oxygen balance in sickle cell
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early trial tests crizanlizumab (a medicine for sickle cell) to see if it improves how your body matches oxygen supply with oxygen needs. It may be helpful for reducing sickle-cell–related complications by changing blood vessel and oxygen behavior.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have sickle cell disease type SS or Sß0 (not other sickle cell types).
- Be age 16 or older, and be able to give/allow consent from a parent or legal guardian (or yourself if applicable).
- Be able to complete MRI scans without needing sedation (sleeping medicines).
- Have not had a severe pain crisis in the last 4 weeks that needed an ER visit, hospital stay, or injection pain medicine.
- Not have had a blood transfusion in the last 4 weeks, and not need ongoing (chronic) transfusions.
- Not be pregnant, and do not have a seizure disorder; also you must be able to cooperate with MRI exams.
- Not have a known allergy or other reason you cannot take crizanlizumab (the trial medicine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.